Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Greaves

Podiatrist, Foot & Ankle Surgery Cherokee, IA Doctor of Podiatric Medicine

NPI 1134617442 CMS profile 7229362

300 Sioux Valley Dr, Cherokee, IA 51012

Open in the dashboard

General payments

$23,099

100 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Greaves of Cherokee, IA is reported in the CMS Open Payments database as having received $23,099 across 100 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $224 7
2024 General $647 17
2023 General $453 11
2022 General $14,087 34
2021 General $6,420 27
2020 General $1,008 1
2019 General $259 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Greaves
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to John Greaves were reported at $224. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year John Greaves Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $259 $389 $118–$1,406 $163
2020 $1,008 $191 $62–$691 $114
2021 $6,420 $329 $104–$1,341 $132
2022 $14,087 $419 $125–$1,611 $149
2023 $453 $377 $128–$1,164 $160
2024 $647 $394 $134–$1,168 $164
2025 $224 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Arthrex, Inc. $13,804 12 payments
  2. Stryker Corporation $2,730 45 payments
  3. Southern Edge Orthopaedics, Inc. $2,208 2 payments
  4. Novus Surgical Solutions LLC $1,582 4 payments
  5. Paragon 28, Inc. $1,532 12 payments
  6. Linvatec Corporation $231 2 payments
  7. Smith+Nephew, Inc. $174 4 payments
  8. DePuy Synthes Sales Inc. $161 2 payments
  9. Nevro Corp. $137 1 payment
  10. Horizon Therapeutics plc $116 1 payment
  11. Other $425 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Grant $10,000 1 payment
  2. Education $6,471 9 payments
  3. Food and Beverage $3,950 76 payments
  4. Travel and Lodging $2,678 14 payments
Products named General payments · program years 2019–2025
  1. Product Portfolio $657 3 payments
  2. PORTFOLIO $628 4 payments
  3. INBONE $516 3 payments
  4. VARIAX $515 4 payments
  5. INFINITY $301 5 payments
  6. CITREFIX $236 3 payments
  7. CLAW II $201 2 payments
  8. STAR $197 1 payment
  9. TENOTAC $193 3 payments
  10. ORTHOLOC 3DI $188 3 payments
  11. Other $3,222 71 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

211

Median for Podiatry: 160

Drug cost

$2,461

Median for Podiatry: $2,368

Branded share of claims

0%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ciclopirox Generic 55 $1,697
Celecoxib Generic 13 $151
Cephalexin Generic 14 $133
Terbinafine Hcl Generic 17 $109
Levofloxacin Generic 25 $93
Gabapentin Generic 13 $85
Clindamycin Hcl Generic 12 $73
Oxycodone Hcl Generic 23 $53
Prednisone Generic 20 $47
Meloxicam Generic 19 $19

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Records

100 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in Iowa

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record